Global Thalassemia Market

Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplants), Patients (Adults, Paediatric) Players and Region - Global Market Outlook to 2032

Thalassemia Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Thalassemia
Thalassemia is a general term for a group of monogenic blood disorders, within which the body produces abnormal hemoglobin, leading to the destruction of red blood cells. This ultimately results in anemia. There are 2 main kinds of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being additional serious. Beta-thalassemia is a common chromosome recessive disorder worldwide and it's comparatively rare within the U.S. Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet want for a reliable treatment possibility still exists. Treatment of thalassemia is usually restricted to regular blood transfusions and iron chelation medical aid. Medication prescribed for hypochromic anemia largely cures symptoms and facet effects like anemia, pathology, and nutrition deficiency. However, gene medical aid is rising as a reliable treatment option for the disease.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


The Thalassemia market would increase in the coming years due to the increasing prevalence of the disease. The rising knowledge and the research and development in this field are fueling the growth of the market. Many patients are dependent on transfusion, which is driving the growth of the market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Thalassemia market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bluebird bio, Inc. (United States), Acceleron Pharma, Inc. (United States), Celgene Corporation (United States), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), Gamida Cell (Israel), Kiadis Pharma (Netherlands), La Jolla Pharmaceutical Company (United States) and IONIS Pharmaceuticals (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Thalassemia market by Type (Alpha-Thalassemia and Beta Thalassemia), Application (Hospital, Clinic, Research Institute and Laboratories) and Region.



On the basis of geography, the market of Thalassemia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Blood Transfusions will boost the Thalassemia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Patients, the sub-segment i.e. Adults will boost the Thalassemia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of The Transplants and Increased Awareness

Market Growth Drivers:
Growing Prevalence of Thalassemia, Increasing Market of Bone Marrow Transplant, Large Numbers of Transfusion Dependent Patients and Escalating Healthcare Spending

Challenges:
Lack of Skilled Personnel

Restraints:
High Cost of The Treatment

Opportunities:
Rising Expenditure on Pharmaceuticals Research and Development




Key Target Audience
Manufacturers of Thalassemia, Suppliers and distributors of Thalassemia, Governmental and Regulatory bodies, End-Users and Potential Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Alpha-Thalassemia
  • Beta Thalassemia
By Application
  • Hospital
  • Clinic
  • Research Institute
  • Laboratories
By Treatment Type
  • Blood Transfusions
  • Iron Chelation Therapy
  • Folic Acid Supplements
  • Gene Therapy
  • Bone Marrow Transplants

By Patients
  • Adults
  • Paediatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Thalassemia
      • 3.2.2. Increasing Market of Bone Marrow Transplant
      • 3.2.3. Large Numbers of Transfusion Dependent Patients
      • 3.2.4. Escalating Healthcare Spending
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Personnel
    • 3.4. Market Trends
      • 3.4.1. Adoption of The Transplants and Increased Awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thalassemia, by Type, Application, Treatment Type, Patients and Region (value and price ) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Thalassemia (Value)
      • 5.2.1. Global Thalassemia by: Type (Value)
        • 5.2.1.1. Alpha-Thalassemia
        • 5.2.1.2. Beta Thalassemia
      • 5.2.2. Global Thalassemia by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Research Institute
        • 5.2.2.4. Laboratories
      • 5.2.3. Global Thalassemia by: Treatment Type (Value)
        • 5.2.3.1. Blood Transfusions
        • 5.2.3.2. Iron Chelation Therapy
        • 5.2.3.3. Folic Acid Supplements
        • 5.2.3.4. Gene Therapy
        • 5.2.3.5. Bone Marrow Transplants
      • 5.2.4. Global Thalassemia by: Patients (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Paediatric
      • 5.2.5. Global Thalassemia Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Thalassemia (Price)
      • 5.3.1. Global Thalassemia by: Type (Price)
  • 6. Thalassemia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bluebird bio, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Acceleron Pharma, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Incyte Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gamida Cell (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Kiadis Pharma (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. La Jolla Pharmaceutical Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. IONIS Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Thalassemia Sale, by Type, Application, Treatment Type, Patients and Region (value and price ) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Thalassemia (Value)
      • 7.2.1. Global Thalassemia by: Type (Value)
        • 7.2.1.1. Alpha-Thalassemia
        • 7.2.1.2. Beta Thalassemia
      • 7.2.2. Global Thalassemia by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Research Institute
        • 7.2.2.4. Laboratories
      • 7.2.3. Global Thalassemia by: Treatment Type (Value)
        • 7.2.3.1. Blood Transfusions
        • 7.2.3.2. Iron Chelation Therapy
        • 7.2.3.3. Folic Acid Supplements
        • 7.2.3.4. Gene Therapy
        • 7.2.3.5. Bone Marrow Transplants
      • 7.2.4. Global Thalassemia by: Patients (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Paediatric
      • 7.2.5. Global Thalassemia Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Thalassemia (Price)
      • 7.3.1. Global Thalassemia by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thalassemia: by Type(USD Million)
  • Table 2. Thalassemia Alpha-Thalassemia , by Region USD Million (2019-2024)
  • Table 3. Thalassemia Beta Thalassemia , by Region USD Million (2019-2024)
  • Table 4. Thalassemia: by Application(USD Million)
  • Table 5. Thalassemia Hospital , by Region USD Million (2019-2024)
  • Table 6. Thalassemia Clinic , by Region USD Million (2019-2024)
  • Table 7. Thalassemia Research Institute , by Region USD Million (2019-2024)
  • Table 8. Thalassemia Laboratories , by Region USD Million (2019-2024)
  • Table 9. Thalassemia: by Treatment Type(USD Million)
  • Table 10. Thalassemia Blood Transfusions , by Region USD Million (2019-2024)
  • Table 11. Thalassemia Iron Chelation Therapy , by Region USD Million (2019-2024)
  • Table 12. Thalassemia Folic Acid Supplements , by Region USD Million (2019-2024)
  • Table 13. Thalassemia Gene Therapy , by Region USD Million (2019-2024)
  • Table 14. Thalassemia Bone Marrow Transplants , by Region USD Million (2019-2024)
  • Table 15. Thalassemia: by Patients(USD Million)
  • Table 16. Thalassemia Adults , by Region USD Million (2019-2024)
  • Table 17. Thalassemia Paediatric , by Region USD Million (2019-2024)
  • Table 18. South America Thalassemia, by Country USD Million (2019-2024)
  • Table 19. South America Thalassemia, by Type USD Million (2019-2024)
  • Table 20. South America Thalassemia, by Application USD Million (2019-2024)
  • Table 21. South America Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 22. South America Thalassemia, by Patients USD Million (2019-2024)
  • Table 23. Brazil Thalassemia, by Type USD Million (2019-2024)
  • Table 24. Brazil Thalassemia, by Application USD Million (2019-2024)
  • Table 25. Brazil Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 26. Brazil Thalassemia, by Patients USD Million (2019-2024)
  • Table 27. Argentina Thalassemia, by Type USD Million (2019-2024)
  • Table 28. Argentina Thalassemia, by Application USD Million (2019-2024)
  • Table 29. Argentina Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 30. Argentina Thalassemia, by Patients USD Million (2019-2024)
  • Table 31. Rest of South America Thalassemia, by Type USD Million (2019-2024)
  • Table 32. Rest of South America Thalassemia, by Application USD Million (2019-2024)
  • Table 33. Rest of South America Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 34. Rest of South America Thalassemia, by Patients USD Million (2019-2024)
  • Table 35. Asia Pacific Thalassemia, by Country USD Million (2019-2024)
  • Table 36. Asia Pacific Thalassemia, by Type USD Million (2019-2024)
  • Table 37. Asia Pacific Thalassemia, by Application USD Million (2019-2024)
  • Table 38. Asia Pacific Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 39. Asia Pacific Thalassemia, by Patients USD Million (2019-2024)
  • Table 40. China Thalassemia, by Type USD Million (2019-2024)
  • Table 41. China Thalassemia, by Application USD Million (2019-2024)
  • Table 42. China Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 43. China Thalassemia, by Patients USD Million (2019-2024)
  • Table 44. Japan Thalassemia, by Type USD Million (2019-2024)
  • Table 45. Japan Thalassemia, by Application USD Million (2019-2024)
  • Table 46. Japan Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 47. Japan Thalassemia, by Patients USD Million (2019-2024)
  • Table 48. India Thalassemia, by Type USD Million (2019-2024)
  • Table 49. India Thalassemia, by Application USD Million (2019-2024)
  • Table 50. India Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 51. India Thalassemia, by Patients USD Million (2019-2024)
  • Table 52. South Korea Thalassemia, by Type USD Million (2019-2024)
  • Table 53. South Korea Thalassemia, by Application USD Million (2019-2024)
  • Table 54. South Korea Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 55. South Korea Thalassemia, by Patients USD Million (2019-2024)
  • Table 56. Taiwan Thalassemia, by Type USD Million (2019-2024)
  • Table 57. Taiwan Thalassemia, by Application USD Million (2019-2024)
  • Table 58. Taiwan Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 59. Taiwan Thalassemia, by Patients USD Million (2019-2024)
  • Table 60. Australia Thalassemia, by Type USD Million (2019-2024)
  • Table 61. Australia Thalassemia, by Application USD Million (2019-2024)
  • Table 62. Australia Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 63. Australia Thalassemia, by Patients USD Million (2019-2024)
  • Table 64. Rest of Asia-Pacific Thalassemia, by Type USD Million (2019-2024)
  • Table 65. Rest of Asia-Pacific Thalassemia, by Application USD Million (2019-2024)
  • Table 66. Rest of Asia-Pacific Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 67. Rest of Asia-Pacific Thalassemia, by Patients USD Million (2019-2024)
  • Table 68. Europe Thalassemia, by Country USD Million (2019-2024)
  • Table 69. Europe Thalassemia, by Type USD Million (2019-2024)
  • Table 70. Europe Thalassemia, by Application USD Million (2019-2024)
  • Table 71. Europe Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 72. Europe Thalassemia, by Patients USD Million (2019-2024)
  • Table 73. Germany Thalassemia, by Type USD Million (2019-2024)
  • Table 74. Germany Thalassemia, by Application USD Million (2019-2024)
  • Table 75. Germany Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 76. Germany Thalassemia, by Patients USD Million (2019-2024)
  • Table 77. France Thalassemia, by Type USD Million (2019-2024)
  • Table 78. France Thalassemia, by Application USD Million (2019-2024)
  • Table 79. France Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 80. France Thalassemia, by Patients USD Million (2019-2024)
  • Table 81. Italy Thalassemia, by Type USD Million (2019-2024)
  • Table 82. Italy Thalassemia, by Application USD Million (2019-2024)
  • Table 83. Italy Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 84. Italy Thalassemia, by Patients USD Million (2019-2024)
  • Table 85. United Kingdom Thalassemia, by Type USD Million (2019-2024)
  • Table 86. United Kingdom Thalassemia, by Application USD Million (2019-2024)
  • Table 87. United Kingdom Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 88. United Kingdom Thalassemia, by Patients USD Million (2019-2024)
  • Table 89. Netherlands Thalassemia, by Type USD Million (2019-2024)
  • Table 90. Netherlands Thalassemia, by Application USD Million (2019-2024)
  • Table 91. Netherlands Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 92. Netherlands Thalassemia, by Patients USD Million (2019-2024)
  • Table 93. Rest of Europe Thalassemia, by Type USD Million (2019-2024)
  • Table 94. Rest of Europe Thalassemia, by Application USD Million (2019-2024)
  • Table 95. Rest of Europe Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 96. Rest of Europe Thalassemia, by Patients USD Million (2019-2024)
  • Table 97. MEA Thalassemia, by Country USD Million (2019-2024)
  • Table 98. MEA Thalassemia, by Type USD Million (2019-2024)
  • Table 99. MEA Thalassemia, by Application USD Million (2019-2024)
  • Table 100. MEA Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 101. MEA Thalassemia, by Patients USD Million (2019-2024)
  • Table 102. Middle East Thalassemia, by Type USD Million (2019-2024)
  • Table 103. Middle East Thalassemia, by Application USD Million (2019-2024)
  • Table 104. Middle East Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 105. Middle East Thalassemia, by Patients USD Million (2019-2024)
  • Table 106. Africa Thalassemia, by Type USD Million (2019-2024)
  • Table 107. Africa Thalassemia, by Application USD Million (2019-2024)
  • Table 108. Africa Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 109. Africa Thalassemia, by Patients USD Million (2019-2024)
  • Table 110. North America Thalassemia, by Country USD Million (2019-2024)
  • Table 111. North America Thalassemia, by Type USD Million (2019-2024)
  • Table 112. North America Thalassemia, by Application USD Million (2019-2024)
  • Table 113. North America Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 114. North America Thalassemia, by Patients USD Million (2019-2024)
  • Table 115. United States Thalassemia, by Type USD Million (2019-2024)
  • Table 116. United States Thalassemia, by Application USD Million (2019-2024)
  • Table 117. United States Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 118. United States Thalassemia, by Patients USD Million (2019-2024)
  • Table 119. Canada Thalassemia, by Type USD Million (2019-2024)
  • Table 120. Canada Thalassemia, by Application USD Million (2019-2024)
  • Table 121. Canada Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 122. Canada Thalassemia, by Patients USD Million (2019-2024)
  • Table 123. Mexico Thalassemia, by Type USD Million (2019-2024)
  • Table 124. Mexico Thalassemia, by Application USD Million (2019-2024)
  • Table 125. Mexico Thalassemia, by Treatment Type USD Million (2019-2024)
  • Table 126. Mexico Thalassemia, by Patients USD Million (2019-2024)
  • Table 127. Thalassemia: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Thalassemia: by Type(USD Million)
  • Table 138. Thalassemia Alpha-Thalassemia , by Region USD Million (2027-2032)
  • Table 139. Thalassemia Beta Thalassemia , by Region USD Million (2027-2032)
  • Table 140. Thalassemia: by Application(USD Million)
  • Table 141. Thalassemia Hospital , by Region USD Million (2027-2032)
  • Table 142. Thalassemia Clinic , by Region USD Million (2027-2032)
  • Table 143. Thalassemia Research Institute , by Region USD Million (2027-2032)
  • Table 144. Thalassemia Laboratories , by Region USD Million (2027-2032)
  • Table 145. Thalassemia: by Treatment Type(USD Million)
  • Table 146. Thalassemia Blood Transfusions , by Region USD Million (2027-2032)
  • Table 147. Thalassemia Iron Chelation Therapy , by Region USD Million (2027-2032)
  • Table 148. Thalassemia Folic Acid Supplements , by Region USD Million (2027-2032)
  • Table 149. Thalassemia Gene Therapy , by Region USD Million (2027-2032)
  • Table 150. Thalassemia Bone Marrow Transplants , by Region USD Million (2027-2032)
  • Table 151. Thalassemia: by Patients(USD Million)
  • Table 152. Thalassemia Adults , by Region USD Million (2027-2032)
  • Table 153. Thalassemia Paediatric , by Region USD Million (2027-2032)
  • Table 154. South America Thalassemia, by Country USD Million (2027-2032)
  • Table 155. South America Thalassemia, by Type USD Million (2027-2032)
  • Table 156. South America Thalassemia, by Application USD Million (2027-2032)
  • Table 157. South America Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 158. South America Thalassemia, by Patients USD Million (2027-2032)
  • Table 159. Brazil Thalassemia, by Type USD Million (2027-2032)
  • Table 160. Brazil Thalassemia, by Application USD Million (2027-2032)
  • Table 161. Brazil Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 162. Brazil Thalassemia, by Patients USD Million (2027-2032)
  • Table 163. Argentina Thalassemia, by Type USD Million (2027-2032)
  • Table 164. Argentina Thalassemia, by Application USD Million (2027-2032)
  • Table 165. Argentina Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 166. Argentina Thalassemia, by Patients USD Million (2027-2032)
  • Table 167. Rest of South America Thalassemia, by Type USD Million (2027-2032)
  • Table 168. Rest of South America Thalassemia, by Application USD Million (2027-2032)
  • Table 169. Rest of South America Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 170. Rest of South America Thalassemia, by Patients USD Million (2027-2032)
  • Table 171. Asia Pacific Thalassemia, by Country USD Million (2027-2032)
  • Table 172. Asia Pacific Thalassemia, by Type USD Million (2027-2032)
  • Table 173. Asia Pacific Thalassemia, by Application USD Million (2027-2032)
  • Table 174. Asia Pacific Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 175. Asia Pacific Thalassemia, by Patients USD Million (2027-2032)
  • Table 176. China Thalassemia, by Type USD Million (2027-2032)
  • Table 177. China Thalassemia, by Application USD Million (2027-2032)
  • Table 178. China Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 179. China Thalassemia, by Patients USD Million (2027-2032)
  • Table 180. Japan Thalassemia, by Type USD Million (2027-2032)
  • Table 181. Japan Thalassemia, by Application USD Million (2027-2032)
  • Table 182. Japan Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 183. Japan Thalassemia, by Patients USD Million (2027-2032)
  • Table 184. India Thalassemia, by Type USD Million (2027-2032)
  • Table 185. India Thalassemia, by Application USD Million (2027-2032)
  • Table 186. India Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 187. India Thalassemia, by Patients USD Million (2027-2032)
  • Table 188. South Korea Thalassemia, by Type USD Million (2027-2032)
  • Table 189. South Korea Thalassemia, by Application USD Million (2027-2032)
  • Table 190. South Korea Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 191. South Korea Thalassemia, by Patients USD Million (2027-2032)
  • Table 192. Taiwan Thalassemia, by Type USD Million (2027-2032)
  • Table 193. Taiwan Thalassemia, by Application USD Million (2027-2032)
  • Table 194. Taiwan Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 195. Taiwan Thalassemia, by Patients USD Million (2027-2032)
  • Table 196. Australia Thalassemia, by Type USD Million (2027-2032)
  • Table 197. Australia Thalassemia, by Application USD Million (2027-2032)
  • Table 198. Australia Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 199. Australia Thalassemia, by Patients USD Million (2027-2032)
  • Table 200. Rest of Asia-Pacific Thalassemia, by Type USD Million (2027-2032)
  • Table 201. Rest of Asia-Pacific Thalassemia, by Application USD Million (2027-2032)
  • Table 202. Rest of Asia-Pacific Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 203. Rest of Asia-Pacific Thalassemia, by Patients USD Million (2027-2032)
  • Table 204. Europe Thalassemia, by Country USD Million (2027-2032)
  • Table 205. Europe Thalassemia, by Type USD Million (2027-2032)
  • Table 206. Europe Thalassemia, by Application USD Million (2027-2032)
  • Table 207. Europe Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 208. Europe Thalassemia, by Patients USD Million (2027-2032)
  • Table 209. Germany Thalassemia, by Type USD Million (2027-2032)
  • Table 210. Germany Thalassemia, by Application USD Million (2027-2032)
  • Table 211. Germany Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 212. Germany Thalassemia, by Patients USD Million (2027-2032)
  • Table 213. France Thalassemia, by Type USD Million (2027-2032)
  • Table 214. France Thalassemia, by Application USD Million (2027-2032)
  • Table 215. France Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 216. France Thalassemia, by Patients USD Million (2027-2032)
  • Table 217. Italy Thalassemia, by Type USD Million (2027-2032)
  • Table 218. Italy Thalassemia, by Application USD Million (2027-2032)
  • Table 219. Italy Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 220. Italy Thalassemia, by Patients USD Million (2027-2032)
  • Table 221. United Kingdom Thalassemia, by Type USD Million (2027-2032)
  • Table 222. United Kingdom Thalassemia, by Application USD Million (2027-2032)
  • Table 223. United Kingdom Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 224. United Kingdom Thalassemia, by Patients USD Million (2027-2032)
  • Table 225. Netherlands Thalassemia, by Type USD Million (2027-2032)
  • Table 226. Netherlands Thalassemia, by Application USD Million (2027-2032)
  • Table 227. Netherlands Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 228. Netherlands Thalassemia, by Patients USD Million (2027-2032)
  • Table 229. Rest of Europe Thalassemia, by Type USD Million (2027-2032)
  • Table 230. Rest of Europe Thalassemia, by Application USD Million (2027-2032)
  • Table 231. Rest of Europe Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 232. Rest of Europe Thalassemia, by Patients USD Million (2027-2032)
  • Table 233. MEA Thalassemia, by Country USD Million (2027-2032)
  • Table 234. MEA Thalassemia, by Type USD Million (2027-2032)
  • Table 235. MEA Thalassemia, by Application USD Million (2027-2032)
  • Table 236. MEA Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 237. MEA Thalassemia, by Patients USD Million (2027-2032)
  • Table 238. Middle East Thalassemia, by Type USD Million (2027-2032)
  • Table 239. Middle East Thalassemia, by Application USD Million (2027-2032)
  • Table 240. Middle East Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 241. Middle East Thalassemia, by Patients USD Million (2027-2032)
  • Table 242. Africa Thalassemia, by Type USD Million (2027-2032)
  • Table 243. Africa Thalassemia, by Application USD Million (2027-2032)
  • Table 244. Africa Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 245. Africa Thalassemia, by Patients USD Million (2027-2032)
  • Table 246. North America Thalassemia, by Country USD Million (2027-2032)
  • Table 247. North America Thalassemia, by Type USD Million (2027-2032)
  • Table 248. North America Thalassemia, by Application USD Million (2027-2032)
  • Table 249. North America Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 250. North America Thalassemia, by Patients USD Million (2027-2032)
  • Table 251. United States Thalassemia, by Type USD Million (2027-2032)
  • Table 252. United States Thalassemia, by Application USD Million (2027-2032)
  • Table 253. United States Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 254. United States Thalassemia, by Patients USD Million (2027-2032)
  • Table 255. Canada Thalassemia, by Type USD Million (2027-2032)
  • Table 256. Canada Thalassemia, by Application USD Million (2027-2032)
  • Table 257. Canada Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 258. Canada Thalassemia, by Patients USD Million (2027-2032)
  • Table 259. Mexico Thalassemia, by Type USD Million (2027-2032)
  • Table 260. Mexico Thalassemia, by Application USD Million (2027-2032)
  • Table 261. Mexico Thalassemia, by Treatment Type USD Million (2027-2032)
  • Table 262. Mexico Thalassemia, by Patients USD Million (2027-2032)
  • Table 263. Thalassemia: by Type(USD/Units)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thalassemia: by Type USD Million (2019-2024)
  • Figure 5. Global Thalassemia: by Application USD Million (2019-2024)
  • Figure 6. Global Thalassemia: by Treatment Type USD Million (2019-2024)
  • Figure 7. Global Thalassemia: by Patients USD Million (2019-2024)
  • Figure 8. South America Thalassemia Share (%), by Country
  • Figure 9. Asia Pacific Thalassemia Share (%), by Country
  • Figure 10. Europe Thalassemia Share (%), by Country
  • Figure 11. MEA Thalassemia Share (%), by Country
  • Figure 12. North America Thalassemia Share (%), by Country
  • Figure 13. Global Thalassemia: by Type USD/Units (2019-2024)
  • Figure 14. Global Thalassemia share by Players 2024 (%)
  • Figure 15. Global Thalassemia share by Players (Top 3) 2024(%)
  • Figure 16. Global Thalassemia share by Players (Top 5) 2024(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bluebird bio, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bluebird bio, Inc. (United States) Revenue: by Geography 2024
  • Figure 20. Acceleron Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Acceleron Pharma, Inc. (United States) Revenue: by Geography 2024
  • Figure 22. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Celgene Corporation (United States) Revenue: by Geography 2024
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2024
  • Figure 26. Incyte Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Incyte Corporation (United States) Revenue: by Geography 2024
  • Figure 28. Gamida Cell (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Gamida Cell (Israel) Revenue: by Geography 2024
  • Figure 30. Kiadis Pharma (Netherlands) Revenue, Net Income and Gross profit
  • Figure 31. Kiadis Pharma (Netherlands) Revenue: by Geography 2024
  • Figure 32. La Jolla Pharmaceutical Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. La Jolla Pharmaceutical Company (United States) Revenue: by Geography 2024
  • Figure 34. IONIS Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 35. IONIS Pharmaceuticals (United States) Revenue: by Geography 2024
  • Figure 36. Global Thalassemia: by Type USD Million (2027-2032)
  • Figure 37. Global Thalassemia: by Application USD Million (2027-2032)
  • Figure 38. Global Thalassemia: by Treatment Type USD Million (2027-2032)
  • Figure 39. Global Thalassemia: by Patients USD Million (2027-2032)
  • Figure 40. South America Thalassemia Share (%), by Country
  • Figure 41. Asia Pacific Thalassemia Share (%), by Country
  • Figure 42. Europe Thalassemia Share (%), by Country
  • Figure 43. MEA Thalassemia Share (%), by Country
  • Figure 44. North America Thalassemia Share (%), by Country
  • Figure 45. Global Thalassemia: by Type USD/Units (2027-2032)
List of companies from research coverage that are profiled in the study
  • Bluebird bio, Inc. (United States)
  • Acceleron Pharma, Inc. (United States)
  • Celgene Corporation (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Incyte Corporation (United States)
  • Gamida Cell (Israel)
  • Kiadis Pharma (Netherlands)
  • La Jolla Pharmaceutical Company (United States)
  • IONIS Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


May 2021 209 Pages 88 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Thalassemia Market Quantitative research analysis
Global Thalassemia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bluebird bio, Inc. (United States), Acceleron Pharma, Inc. (United States), Celgene Corporation (United States), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), Gamida Cell (Israel), Kiadis Pharma (Netherlands), La Jolla Pharmaceutical Company (United States) and IONIS Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of The Transplants and Increased Awareness" is seen as one of major influencing trends for Thalassemia Market during projected period 2024-2032.
The Thalassemia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Thalassemia Market Report?

Have a Query? Click Here

Other Related Reports

Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiat...
$ 3750
Appendix Cancer Treatment Comprehensive Study by Type (Neuroendocrine Tumors, Carcinomas, Mucinous Adenocarcinoma (low grade, high grade), Global Cell Carcinoids, Intestinal Type Adenocarcinoma, Sign...
$ 3750
Diabetes Therapeutics and Diagnostics Comprehensive Study by Type (Injectable (Insulin, Amylinomimetic), Oral (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl ...
$ 3750
Daptomycin Comprehensive Study by Type (350 mg lyophilized powder, 500 mg lyophilized powder), Application (Adult, Pediatric patients (1 to 17 years of age)), End -Users (Pharmaceuticals, Clinics, We...
$ 3500
Epistaxis Comprehensive Study by Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Application (Anterior Epistaxis, Posterior Epistaxis), Treatment (Medication, ...
$ 3650
Krabbe Disease Treatment Comprehensive Study by Type (Infantile (occurs in babies less than six months of age), Late-onset (can happen at any other time)), Diagnosed Test (Imaging Scans (MRI), Nerve ...
$ 3500